Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Issac Sachmechi is active.

Publication


Featured researches published by Issac Sachmechi.


Endocrine Practice | 2007

Effect of Proton Pump Inhibitors on Serum Thyroid-Stimulating Hormone Level in Euthyroid Patients Treated with Levothyroxine for Hypothyroidism

Issac Sachmechi; David L. Reich; Michael Aninyei; Francisca Wibowo; Garima Gupta; Paul Kim

OBJECTIVE To examine retrospectively the effect of proton pump inhibitors (PPIs) on thyrotropin (thyroid-stimulating hormone or TSH) values in patients with hypothyroidism and normal TSH levels receiving levothyroxine (LT4) replacement therapy. METHODS The data collection was done by retrospective review of electronic medical records from the period of December 2002 to August 2005 from patients with hypothyroidism who were receiving at least 25 mug of LT4 replacement daily at Queens Hospital Center. The first 92 patients meeting all inclusion and exclusion criteria were included in the study. The study group (N = 37) patient data were collected by selecting euthyroid patients who had received stable LT4 replacement for at least 6 months and in whom PPI therapy (lansoprazole) was later initiated. TSH levels were collected before and at least 2 months after the PPI treatment was started. The control group (N = 55) patient data were collected by reviewing TSH levels among euthyroid patients with a history of hypothyroidism receiving stable LT4 therapy and not receiving a PPI during the period of data collection. The statistical analysis was done by comparing the mean change in TSH level in each group with use of the Student t test. RESULTS In the study group, the mean change in the TSH level from before to at least 2 months after initiation of PPI therapy, 0.69 +/- 1.9 micro IU/mL, was statistically significant (P = 0.035). In the control group, the mean change in the TSH level during the study period, 0.11 +/- 1.06 micro IU/mL, was not statistically significant (P = 0.45). CONCLUSION To our best knowledge, this is the first study in humans with hypothyroidism demonstrating the effect of PPIs on serum TSH levels. PPIs should be added to the list of medications affecting the level of thyroid hormone in patients with hypothyroidism treated with LT4 replacement. Patients with hypothyroidism and normal TSH values during LT4 replacement therapy may need additional thyroid function testing after treatment with PPIs and may need adjustment of their LT4 dose.


American Journal of Medical Genetics | 1998

An adult with 49,XYYYY karyotype: Case report and endocrine studies

Alan Shanske; Issac Sachmechi; Dinesh K. Patel; Alka Bishnoi; Fred Rosner

Sex chromosome abnormalities, such as 47,XXX, 47,XXY, 47,XYY, and 45,X, are relatively common and occur in approximately 1 of 400 births. Sex chromosome tetrasomy and pentasomy are much rarer events. The somatic and developmental consequences of supernumerary sex chromosomes have not been studied adequately. This is especially true of individuals with only supernumerary Y chromosomes. Based on available case reports, the effects of extra Y chromosomes appear not as severe as those of supernumerary X chromosomes. Only two case reports of nonmosaic tetrasomy of the Y chromosome have been published. We evaluated a 30-year-old man with a 49,XYYYY karyotype and assessed his severe physical and mental handicaps (particularly the endocrine abnormalities) and attempted to clarify the effects of extra Y chromosomes on growth, development, and behavior.


American Journal of Case Reports | 2015

Follicular Variant of Papillary Thyroid Cancer with Bilateral Renal Metastases Discovered Incidentally During Work-Up of Primary Endometrial Cancer: A Rare Occurrence

Sandeep Singh Lubana; Navdeep Singh; Sandeep S. Tuli; Tayyaba Bashir; Issac Sachmechi; Margaret M. Kemeny

Patient: Female, 70 Final Diagnosis: Follicular variant of papillary thyroid cancer with renal metastases Symptoms: Bleeding per vaginum Medication: — Clinical Procedure: Total thyroidectomy Specialty: Oncology Objective: Rare disease Background: Follicular variant of papillary thyroid cancer (FV-PTC) is the second most common subtype of papillary thyroid cancer (PTC) after classic PTC. FV-PTC is characterized by nuclear features consistent with classic PTC but has a follicular architecture that lacks classic papillary morphology. Thyroid cancer rarely metastasizes to the kidney. Only 6 cases of FV-PTC metastasizing to the kidney have been reported in the English literature. We are reporting a case of FV-PTC with bilateral renal metastases discovered incidentally during work-up of primary endometrial cancer. Case Report: A 70-year-old woman presented with post-menopausal bleeding secondary to endometrial cancer. Staging work-up showed multiple bilateral lung nodules, bilateral soft tissue kidney masses, and multinodular goiter. The pathological and immnohistochemical profile of the lung biopsy was consistent with primary well-differentiated lung adenocarcinoma. Follow-up computerized tomography scan showed stable lung nodules and enlarging renal masses, which was suggestive of bilateral renal cancer. While the histologic features of the renal biopsy were not typical, the immunohistochemical staining of renal biopsy was positive for Paired box 8, thyroid transcription factor-1, thyroglobulin, and cytokeratin 7, suggesting the thyroid as the primary cancer site. The final histopathology on surgical specimen of total thyroidectomy revealed follicular variant of papillary thyroid cancer. Conclusions: The presence of pulmonary nodules and kidney masses does not always suggest the lung or the kidney as primary tumor sites. The clinician should be aware of the possibility of metastasis and look for the primary source, which in the present case was FV-PTC. Immunohistochemistry plays an important role in determining the primary site of origin. In case of multiple-organ metastases, each metastatic lesion should be biopsied as soon as possible for definitive diagnosis and appropriate treatment.


AACE clinical case reports | 2015

LEVOTHYROXINE MALABSORPTION INDUCED BY DIABETIC GASTROPARESIS EXACERBATED DURING PREGNANCIES: EFFECT OF INTRAMUSCULAR LEVOTHYROXINE INJECTIONS AND LEVOTHYROXINE SOFT GEL CAPSULES

Paul Kim; Issac Sachmechi

ABSTRACT Objective: We report a case of severe hypothyroidism with levothyroxine (LT4) malabsorption induced by diabetic gastroparesis. This was exacerbated during the patients 2 pregnancies. Management was improved by intramuscular (IM) LT4) injections and LT4 soft gel capsules. Methods: Case report with literature review. Results: A 23-year-old Hispanic female with type 1 diabetes (DM) and hypothyroidism developed diabetic gastroparesis with unpredictable responses to LT4. She had 2 pregnancies during which her oral LT4 was switched to weekly IM injections of LT4 that maintained her euthyroid state. An LT4 absorption test with 1,000 mcg LT4 revealed reduced LT4 absorption. A gastric emptying scan showed delayed emptying, and endoscopy demonstrated a large amount of residual food in the patients stomach after an overnight fast. Weekly IM injections of LT4 and LT4 soft gel capsules maintained her euthyroid state after her last pregnancy with a follow-up longer than 1-year. A repeat LT4 absorption test w...


Case reports in critical care | 2016

Paliperidone Inducing Concomitantly Syndrome of Inappropriate Antidiuretic Hormone, Neuroleptic Malignant Syndrome, and Rhabdomyolysis

Jaspinder Kaur; Dileep Kumar; Mostafa Alfishawy; Ricardo Lopez; Issac Sachmechi

Paliperidone, an active metabolite of risperidone, is a new atypical antipsychotic agent. Syndrome of inappropriate antidiuretic hormone (SIADH), neuroleptic malignant syndrome (NMS), and rhabdomyolysis are the uncommon side effects of psychotropic drugs. We report a case of 35-year-old male with schizoaffective disorder who was admitted for acute-on-chronic exacerbation of his psychotic disorder for which intramuscular paliperidone 234 mg injection was given. Two days later, the patient developed hyponatremic seizures secondary to SIADH which was treated with hypertonic saline. On the third day, he developed high grade fever and severe muscle rigidity with raised creatine phosphokinase (CPK) and liver enzymes levels. He was treated with dantrolene 100 mg, bromocriptine 2.5 mg, and lorazepam 2 mg. Our patient required management of the three rare conditions following treatment with paliperidone. This case highlights the need for health care providers to be aware of the rare, potentially life threatening but preventable hyponatremia, NMS, and rhabdomyolysis as a possible adverse effect of paliperidone.


American Journal of Case Reports | 2017

A Case Report of Cystic Pheochromocytoma

Shoaib Z. Junejo; Sandeep S. Tuli; David M. Heimann; Issac Sachmechi; David L. Reich

Patient: Male, 64 Final Diagnosis: Cystic pheochromocytoma Symptoms: Abdominal pain Medication: — Clinical Procedure: — Specialty: Endocrinology and Metabolic Objective: Rare disease Background: Pheochromocytoma is a rare catecholamine-producing tumor with an estimated incidence of less than 0.1% in the global population. We present a case of cystic pheochromocytoma that was diagnosed as an incidental finding. The patient presented with abdominal pain and had a history of hypertension. Case Report: A 64-year-old man with hypertension presented with a clinical history of intermittent abdominal pain for one year. He denied sweating, palpitations, headache or back pain. He was found to have an elevated blood pressure of 170/90 and no palpable abdominal mass. Contrast-enhanced computed tomography (CT) imaging of the abdomen and pelvis were performed that showed cystic mass measuring 9 cm in diameter arising from the left adrenal gland with contrast-enhancing mural nodules. Magnetic resonance imaging (MRI) confirmed the cystic nature of the mass. Laboratory analysis showed an elevated plasma normetanephrine (NMN) of 1,087 pg/ml and metanephrine (MN) of 372 pg/ml; 24-hour urine showed elevated levels of NMN and MN, 3,002 mg/24 h and 1,596 mg/24 h, respectively. Given the laboratory and radiologic findings, a diagnosis of cystic pheochromocytoma was made. After controlling blood pressure with the alpha-blocker, doxazosin, the patient was hydrated and scheduled for an elective adrenalectomy. The histopathology of the excised adrenal gland was consistent with a cystic pheochromocytoma. Conclusions: Cystic pheochromocytoma is a very rare tumor that may present without symptoms. The clinical course of cystic pheochromocytoma is similar to that of solid pheochromocytoma. Early surgical intervention is recommended, following blood pressure control with an alpha-blocker, and adequate hydration.


Case reports in endocrinology | 2014

Recurrent Silent Thyroiditis as a Sequela of Postpartum Thyroiditis

Preaw Hanseree; Vincent Bryan Salvador; Issac Sachmechi; Paul Kim

Thyroiditis encompasses a group of disorders characterized by thyroid inflammation. Though clinically indistinguishable from silent thyroiditis, postpartum thyroiditis occurs in women within 12 months after delivery. Recurrent postpartum thyroiditis in subsequent pregnancies is common, but recurrent silent thyroiditis is rare. We reported a case of patient with recurrent episodes of thyroiditis, unrelated to pregnancy, after an episode of postpartum thyroiditis. It is of interest that postpartum thyroiditis and silent thyroiditis could occur closely to each other; however, the link between these disorders is not well established. This report is to remind physicians of the possibility of recurrent silent thyroiditis in women with a history of postpartum thyroiditis.


Cureus | 2018

A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia

Amir Shahbaz; Kashif Aziz; Muhammad Umair; Paria Zarghamravanbakhsh; Issac Sachmechi

When very low or undetectable high density lipoprotein (HDL)-cholesterol (HDL-C) is encountered in clinical practice, a paraproteinemia should be suspected in the absence of genetic or more obvious secondary causes. We reported a case of artifactually low HDL-C in a 68-year-old man with a past medical history of vitamin B12 deficiency. Lipid panel showed total cholesterol (TC) 144 mg/dl, triglycerides (TG) 79 mg/dl, HDL-C 5 mg/dl, and low density lipoprotein (LDL) 123 mg/dl. HDL-C, which was determined three years prior to this presentation was found normal. The patient was prescribed extended release nicotinic acid. Further workup performed showed the ratio of APO B/APO A1 0.36 and direct LDL 28 mg/dl. In the absence of genetic or more obvious secondary causes, we hypothesized that low HDL-C in this patient was due to paraprotein interference in vitro with the liquid homogenous HDL assay. Serum protein electrophoresis demonstrated normal IgG and IgA and an abnormally high IgM at 3510 mg/dl (57-266). A bone marrow biopsy revealed Waldenstrom macroglobulinemia. A diagnostic workup for an isolated low HDL-C unmasking the diagnosis of Waldenstrom macroglobulinemia has been rarely reported. Care must be taken when using the homogeneous method for direct measurement of HDL-C as artifactually undetectable HDL-C might result in the mismanagement of patients with paraproteinemia.


Cureus | 2018

Acute Liver Injury Induced by Sitagliptin: Report of Two Cases and Review of Literature

Amir Shahbaz; Kashif Aziz; Muhammad Umair; Mohaddeseh Sharifzadeh; Issac Sachmechi

We present two cases of acute liver injury associated with sitagliptin. The first case was a 58-year-old male with a history of poorly controlled type 2 diabetes mellitus and hyperlipidemia. Sitagliptin was added for better control of diabetes. After initiation of sitagliptin, the patients serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels increased gradually over a period of six months. The second case was a 44-year-old female with type 2 diabetes mellitus, and she experienced a more than ten-fold elevation in ALT and AST levels after starting sitagliptin therapy. Both patients did not have any history of alcohol abuse, acetaminophen use, or chronic liver disease. In the literature review, the reported magnitude of liver enzyme derangement with sitagliptin is generally mild and transient (two-fold upper limit of normal). We believed that the acute derangement of ALT and AST in our patients was due to sitagliptin since the ALT and AST normalized shortly after sitagliptin was discontinued and remained at baseline after resuming all other medications. Further research is needed to understand the mechanism of dipeptidyl peptidase 4 (DPP-4) inhibitors associated liver injury.


Cureus | 2018

Improvement of Chronic Idiopathic Urticaria With Levothyroxine: A Case Report and Review of Literature

Amir Shahbaz; Sri Harshavardhan Senapathi; Kashif Aziz; Muhammad Umair; Amna Khalid; Issac Sachmechi

There is an increased association between chronic urticaria (CU) and thyroid autoantibodies. We presented a case of a patient suffering from CU and newly diagnosed Hashimoto’s thyroiditis in which levothyroxine therapy completely resolved the symptoms of urticaria. A 58-year-old female with a past medical history of recurrent urticaria presented with complaints of fatigue and weight gain. Laboratory investigations showed a high thyroid stimulating hormone (TSH) level and a low free thyroxine (T4) level. She had elevated levels of antithyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies (anti-TG). She was diagnosed as a case of Hashimotos thyroiditis and started on levothyroxine therapy. She noticed that her uncontrolled recurrent urticaria started to get better and after a few months of therapy, she stopped taking her topical ointments and antihistamines. The reason for the association between positive serological tests for thyroid autoimmunity and CU is unclear. The resolution of chronic urticaria with levothyroxine in our patient with Hashimotos thyroiditis suggests a common underlying mechanism between the two pathologies.

Collaboration


Dive into the Issac Sachmechi's collaboration.

Top Co-Authors

Avatar

Amir Shahbaz

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Muhammad Umair

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Kashif Aziz

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Paul Kim

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

David L. Reich

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Afsoon Razavi

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Alka Bishnoi

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Dinesh K. Patel

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Fred Rosner

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Jaspinder Kaur

Icahn School of Medicine at Mount Sinai

View shared research outputs
Researchain Logo
Decentralizing Knowledge